Grufity logoGrufity logo
StocksFundsSearch Filings

Verona Pharma PLC Stock Research

VRNA

21.46USD-0.42(-1.92%)Delayed

Market Summary

USD21.46-0.42
Delayed
-1.92%

VRNA Alerts

VRNA Stock Price

VRNA RSI Chart

VRNA Valuation

Market Cap

13.6B

Price/Earnings (Trailing)

-223.78

Price/Sales (Trailing)

29.6K

EV/EBITDA

-225.3

Price/Free Cashflow

-265.09

VRNA Price/Sales (Trailing)

VRNA Profitability

EBT Margin

-14944.98%

Return on Equity

-29.81%

Return on Assets

-26.48%

Free Cashflow Yield

-0.38%

VRNA Fundamentals

VRNA Revenue

Revenue (TTM)

458.0K

Revenue Q/Q

-30.61%

VRNA Earnings

Earnings (TTM)

-60.6M

Earnings Y/Y

32.59%

Earnings Q/Q

-60.2%

Price Action

52 Week Range

3.8526.44
(Low)(High)

Last 7 days

0.3%

Last 30 days

1.3%

Last 90 days

-4.6%

Trailing 12 Months

383.3%

VRNA Financial Health

Current Ratio

12.77

VRNA Investor Care

Shares Dilution (1Y)

30.86%

Diluted EPS (TTM)

-0.11

Financials for Verona Pharma

Income Statement (Last 12 Months)
Description(%) Q/Q2022Q42022Q22022Q12021Q42021Q3
Revenue-96.6%458,00013,638,66726,819,33340,000,00026,692,000
Gross Profit-99.7%112,00040,000,000160,000,000--
Operating Expenses-29.4%75,862,000107,482,000115,522,000--
  S&GA Expenses-10.2%26,579,00029,606,00032,065,000--
  R&D Expenses-36.7%49,283,00077,876,00083,457,000--
EBITDA-25.1%-67,291,000-53,778,000-58,153,000--
EBITDA Margin-10828.2%-146-1.34-1.45--
Earnings Before Taxes-25.0%-68,448,000-54,776,000-59,132,000--
EBT Margin-10813.5%-149-1.37-1.48--
Interest Expenses50.6%521,000346,000340,000--
Net Income-25.3%-68,701,000-54,814,000-59,116,000--
Net Income Margin-10846.3%-150-1.37-1.48--
Free Cahsflow-109.8%-59,891,000-28,551,000-29,227,000--
Balance Sheet
(In Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Assets24.5%323259275155169
  Current Assets26.3%307243258139153
    Cash Equivalents27.9%291228232112133
  Net PPE-83.6%0.000.000.000.000.00
  Goodwill0%1.001.001.001.001.00
Liabilities60.0%46.0029.0037.0044.0043.00
  Current Liabilities39.4%27.0019.0032.0039.0038.00
    LT Debt, Non Current102.8%20.0010.005.005.005.00
Shareholder's Equity20.1%277230237111126
  Retained Earnings-5.1%-350-333-322-306-288
  Additional Paid-In Capital11.7%591529526391388
Shares Outstanding4.2%632606602485483
Cashflow (Last 12 Months)
(In Thousands)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Cashflow From Operations14.6%-51,132-59,862-69,447-28,527-29,215
  Share Based Compensation3.8%14,66314,12113,80415,92620,323
Cashflow From Investing0%-29.00-29.00-30.00-41.00-12.00
Cashflow From Financing49.3%210,229140,818137,303-4,133-6,843

Risks for VRNA

What is the probability of a big loss on VRNA?

100%


Probability that Verona Pharma stock will be more than 20% underwater in next one year

100%


Probability that Verona Pharma stock will be more than 30% underwater in next one year.

87.7%


Probability that Verona Pharma stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does VRNA drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Verona Pharma was unfortunately bought at previous high price.

Drawdowns

Returns for VRNA

Cumulative Returns on VRNA

5.2%


5-Year Cumulative Returns

64.4%


3-Year Cumulative Returns

What are the long-term rolling returns for VRNA?

FIve years rolling returns for Verona Pharma.

Annualized Returns

Which funds bought or sold VRNA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-05-18
NEW YORK STATE COMMON RETIREMENT FUND
new
-
143,000
143,000
-%
2023-05-18
JPMORGAN CHASE & CO
added
11,167
4,319,000
4,369,000
-%
2023-05-16
PERCEPTIVE ADVISORS LLC
reduced
-43.99
-72,638,700
54,894,500
1.62%
2023-05-15
Samsara BioCapital, LLC
unchanged
-
-4,204,760
13,955,600
2.87%
2023-05-15
CITADEL ADVISORS LLC
new
-
5,386,420
5,386,420
-%
2023-05-15
ORBIMED ADVISORS LLC
reduced
-6.81
-33,919,200
85,554,700
1.68%
2023-05-15
Affinity Asset Advisors, LLC
added
44.9
927,073
9,092,650
3.00%
2023-05-15
Artia Global Partners LP
added
126
772,336
1,816,260
0.67%
2023-05-15
Caligan Partners LP
unchanged
-
-1,107,540
3,675,920
2.56%
2023-05-15
Shay Capital LLC
new
-
271,080
271,080
0.05%

1–10 of 41

Latest Funds Activity

Are funds buying VRNA calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own VRNA
No. of Funds

Verona Pharma News

Defense World
Witte Jan De Buys 7792 Shares of Integra LifeSciences Holdings Co ....
Defense World,
106 minutes ago
Defense World
InvestorsObserver
Investing.com UK

Schedule 13G FIlings of Verona Pharma

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
May 16, 2023
orbimed advisors llc
4.8%
3,777,778
SC 13D/A
Apr 25, 2023
access industries holdings llc
0%
0
SC 13G/A
Apr 20, 2023
perceptive advisors llc
5.6%
4,462,666
SC 13G
Feb 14, 2023
vivo ventures vii, llc
3.8%
23,142,200
SC 13G/A
Feb 14, 2023
ra capital management, l.p.
9.99%
7,691,990
SC 13G/A
Feb 09, 2023
access industries holdings llc
5.45%
32,946,296
SC 13G/A
Feb 06, 2023
wellington management group llp
4.43%
26,770,960
SC 13G/A
Dec 27, 2022
orbimed advisors llc
5.6%
4,260,691
SC 13D/A
Sep 07, 2022
growth equity opportunities fund iv, llc
7.9%
46,447,651
SC 13D/A
Feb 14, 2022
ra capital management, l.p.
9.99%
48,778,172
SC 13G/A

VRNA Fair Value

Show Fair-Value

Recent SEC filings of Verona Pharma

View All Filings
Date Filed Form Type Document
May 16, 2023
SC 13D/A
13D - Major Acquisition
May 15, 2023
4
Insider Trading
May 15, 2023
4
Insider Trading
May 11, 2023
144
Notice of Insider Sale Intent
May 11, 2023
4/A
Insider Trading
May 11, 2023
4/A
Insider Trading
May 09, 2023
8-K
Current Report
May 09, 2023
S-8
Employee Benefits Plan
May 09, 2023
10-Q
Quarterly Report
May 03, 2023
144
Notice of Insider Sale Intent

Latest Insider Trading transactions for VRNA

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-05-15
Gupta Rishi
sold
-7,222,480
20.0785
-359,713
-
2023-05-15
ORBIMED ADVISORS LLC
sold
-7,222,480
20.0785
-359,713
-
2023-05-12
ORBIMED ADVISORS LLC
sold
-934,848
21.64
-43,200
-
2023-05-12
Gupta Rishi
sold
-934,848
21.64
-43,200
-
2023-05-11
Gupta Rishi
sold
-1,780,800
22.26
-80,000
-
2023-05-11
ORBIMED ADVISORS LLC
sold
-1,780,800
22.26
-80,000
-
2023-05-03
Rickard Kathleen A.
sold
-76,241
2.6517
-28,752
chief medical officer
2023-05-01
Poll Claire
acquired
-
-
8,328
general counsel
2023-05-01
ZACCARDELLI DAVID
sold
-1,173,420
2.5759
-455,536
president and ceo
2023-05-01
Rickard Kathleen A.
acquired
-
-
15,000
chief medical officer

1–10 of 50

About Verona Pharma

David S. Zaccardelli
30
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.

VRNA Income Statement

2023-03-31
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Operating expenses:  
Research and development$ 12,610$ 17,625
Selling, general and administrative9,5897,440
Total operating expenses22,19925,065
Operating loss(22,199)(25,065)
Other income/(expense):  
Research and development tax credit2,3131,302
Interest income2,67715
Interest expense(293)(84)
Foreign exchange gain/(loss)932(923)
Total other income, net5,629310
Loss before income taxes(16,570)(24,755)
Income tax expense(173)(82)
Net loss$ (16,743)$ (24,837)
Profit/(loss) per share, basic (in dollars per share)$ (0.03)$ (0.05)
Profit/(loss) per share, diluted (in dollars per share)$ (0.03)$ (0.05)
Weighted-average shares outstanding, basic (in shares)621,451,000481,942,000
Weighted-average shares outstanding, diluted (in shares)621,451,000481,942,000

VRNA Balance Sheet

2023-03-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 291,415$ 227,827
Prepaid expenses1,5612,499
Tax incentive receivable11,8429,282
Other current assets2,0733,388
Total current assets306,891242,996
Non-current assets:  
Furniture and equipment, net1273
Goodwill545545
Equity interest15,00015,000
Right-of-use assets698854
Total non-current assets16,25516,472
Total assets323,146259,468
Current liabilities:  
Accounts payable7,2372,910
Accrued expenses17,70313,752
Current operating lease liabilities650675
Taxes payable424283
Other current liabilities5091,409
Total current liabilities26,52319,029
Non-current liabilities:  
Term loan19,8099,768
Non-current operating lease liabilities65205
Total non-current liabilities19,8749,973
Total liabilities46,39729,002
Commitments and contingencies
Shareholders' equity:  
Ordinary £0.05 par value shares; 651,659,630 and 631,338,246 issued, and 631,987,078 and 606,301,054 outstanding, at March 31, 2023 and December 31, 2022, respectively41,75340,526
Additional paid-in capital590,915529,187
Ordinary shares held in treasury(1,208)(1,549)
Accumulated other comprehensive loss(4,601)(4,601)
Accumulated deficit(350,110)(333,097)
Total shareholders' equity276,749230,466
Total liabilities and shareholders' equity$ 323,146$ 259,468